All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33160464" target="_blank" >RIV/61989592:15110/16:33160464 - isvavai.cz</a>

  • Alternative codes found

    RIV/75010330:_____/16:00011642

  • Result on the web

    <a href="https://link.springer.com/article/10.1007%2Fs00280-016-3058-y" target="_blank" >https://link.springer.com/article/10.1007%2Fs00280-016-3058-y</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s00280-016-3058-y" target="_blank" >10.1007/s00280-016-3058-y</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.

  • Original language description

    Most patients with pancreatic ductal adenocarcinoma (PDAC) present with unresectable or metastatic disease with very poor prognosis. Chemotherapy is the primary treatment modality for patients with locally advanced and metastatic PDAC, but the efficacy of currently available regimens is limited. Taxanes are widely used in many primary cancers including breast, ovarian and lung cancers. The activity of combined regimen of taxanes plus nucleoside analogue or platinum derivate in terms of response rate ranges between 20 and 57 % in PDAC and may prolong overall survival. Since 2013 nab-paclitaxel (paclitaxel-albumin-bound particles) became a new treatment option for patients with metastatic pancreatic cancer based on the results of MPACT trial. Moreover, encouraging activity in PDAC of the combination regimen of paclitaxel and carboplatin that is being widely used in other solid tumors has been reported recently. Biomarkers, including biomarkers predictive of taxane resistance, could allow individualized tailored therapy. BRCA mutation status could serve as predictor of better chemotherapy treatment outcome in PDAC. The present review summarizes the principal clinical trials evaluating the efficacy of taxanes both as monotherapy and in combination in view of the potential use in the treatment of PDAC.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/NV16-28375A" target="_blank" >NV16-28375A: Study of prognostic and predictive biomarkers in the treatment of pancreatic cancer</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cancer Chemotherapy and Pharmacology

  • ISSN

    0344-5704

  • e-ISSN

  • Volume of the periodical

    78

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    DE - GERMANY

  • Number of pages

    11

  • Pages from-to

    1101-1111

  • UT code for WoS article

    000392322300001

  • EID of the result in the Scopus database